Logo image of USX

US XPRESS ENTERPRISES INC -A (USX) Stock Fundamental Analysis

NYSE:USX - New York Stock Exchange, Inc. - US90338N2027 - Common Stock - Currency: USD

6.14  0 (0%)

After market: 6.14 0 (0%)

Fundamental Rating

1

USX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 39 industry peers in the Ground Transportation industry. Both the profitability and financial health of USX have multiple concerns. USX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

USX had negative earnings in the past year.
USX had a positive operating cash flow in the past year.
In multiple years USX reported negative net income over the last 5 years.
In the past 5 years USX always reported a positive cash flow from operatings.
USX Yearly Net Income VS EBIT VS OCF VS FCFUSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M

1.2 Ratios

The profitability ratios for USX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
USX Yearly ROA, ROE, ROICUSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 20 40

1.3 Margins

Looking at the Gross Margin, with a value of 61.79%, USX is in the better half of the industry, outperforming 72.50% of the companies in the same industry.
In the last couple of years the Gross Margin of USX has declined.
The Profit Margin and Operating Margin are not available for USX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.29%
GM growth 5Y-1.85%
USX Yearly Profit, Operating, Gross MarginsUSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 40 60

More info and screens

0

2. Health

2.1 Basic Checks

USX does not have a ROIC to compare to the WACC, probably because it is not profitable.
USX has more shares outstanding than it did 1 year ago.
USX has a worse debt/assets ratio than last year.
USX Yearly Shares OutstandingUSX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
USX Yearly Total Debt VS Total AssetsUSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M 1B

2.2 Solvency

USX has an Altman-Z score of 1.44. This is a bad value and indicates that USX is not financially healthy and even has some risk of bankruptcy.
USX has a worse Altman-Z score (1.44) than 72.50% of its industry peers.
USX has a Debt/Equity ratio of 1.79. This is a high value indicating a heavy dependency on external financing.
USX's Debt to Equity ratio of 1.79 is on the low side compared to the rest of the industry. USX is outperformed by 67.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.79
Debt/FCF N/A
Altman-Z 1.44
ROIC/WACCN/A
WACC8.23%
USX Yearly LT Debt VS Equity VS FCFUSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M 400M

2.3 Liquidity

USX has a Current Ratio of 0.71. This is a bad value and indicates that USX is not financially healthy enough and could expect problems in meeting its short term obligations.
USX's Current ratio of 0.71 is on the low side compared to the rest of the industry. USX is outperformed by 77.50% of its industry peers.
A Quick Ratio of 0.69 indicates that USX may have some problems paying its short term obligations.
USX's Quick ratio of 0.69 is on the low side compared to the rest of the industry. USX is outperformed by 72.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.69
USX Yearly Current Assets VS Current LiabilitesUSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

USX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1220.00%.
USX shows a small growth in Revenue. In the last year, the Revenue has grown by 6.04%.
Measured over the past years, USX shows a small growth in Revenue. The Revenue has been growing by 6.80% on average per year.
EPS 1Y (TTM)-1220%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2450%
Revenue 1Y (TTM)6.04%
Revenue growth 3Y8.17%
Revenue growth 5Y6.8%
Sales Q2Q%-4.73%

3.2 Future

Based on estimates for the next years, USX will show a very strong growth in Earnings Per Share. The EPS will grow by 47.15% on average per year.
Based on estimates for the next years, USX will show a small growth in Revenue. The Revenue will grow by 3.65% on average per year.
EPS Next Y11.56%
EPS Next 2Y47.89%
EPS Next 3Y47.15%
EPS Next 5YN/A
Revenue Next Year-2.35%
Revenue Next 2Y1.33%
Revenue Next 3Y3.65%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
USX Yearly Revenue VS EstimatesUSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
USX Yearly EPS VS EstimatesUSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 0.5 -0.5 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

USX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
USX is valuated quite expensively with a Price/Forward Earnings ratio of 52.11.
Compared to the rest of the industry, the Price/Forward Earnings ratio of USX indicates a slightly more expensive valuation: USX is more expensive than 67.50% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, USX is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 52.11
USX Price Earnings VS Forward Price EarningsUSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of USX indicates a slightly more expensive valuation: USX is more expensive than 72.50% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 26.23
USX Per share dataUSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
USX's earnings are expected to grow with 47.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.89%
EPS Next 3Y47.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for USX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

US XPRESS ENTERPRISES INC -A

NYSE:USX (6/30/2023, 8:04:00 PM)

After market: 6.14 0 (0%)

6.14

0 (0%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)05-10 2023-05-10/dmh
Earnings (Next)08-01 2023-08-01/amc
Inst Owners2.55%
Inst Owner Change-93.88%
Ins Owners2.58%
Ins Owner Change0%
Market Cap331.91M
Analysts50
Price Target4.74 (-22.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-67.83%
Min EPS beat(2)-100.64%
Max EPS beat(2)-35.01%
EPS beat(4)0
Avg EPS beat(4)-169.34%
Min EPS beat(4)-334.1%
Max EPS beat(4)-35.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.1%
Min Revenue beat(2)-3.07%
Max Revenue beat(2)0.88%
Revenue beat(4)2
Avg Revenue beat(4)-0.64%
Min Revenue beat(4)-3.07%
Max Revenue beat(4)0.88%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)40.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 52.11
P/S 0.16
P/FCF N/A
P/OCF 7.25
P/B 1.56
P/tB 2.55
EV/EBITDA 26.23
EPS(TTM)-1.12
EYN/A
EPS(NY)0.12
Fwd EY1.92%
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)0.85
OCFY13.8%
SpS39.53
BVpS3.94
TBVpS2.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.79%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.29%
GM growth 5Y-1.85%
F-Score4
Asset Turnover1.58
Health
Industry RankSector Rank
Debt/Equity 1.79
Debt/FCF N/A
Debt/EBITDA 16.14
Cap/Depr 222.01%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.69
Altman-Z 1.44
F-Score4
WACC8.23%
ROIC/WACCN/A
Cap/Depr(3y)226.34%
Cap/Depr(5y)218.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1220%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2450%
EPS Next Y11.56%
EPS Next 2Y47.89%
EPS Next 3Y47.15%
EPS Next 5YN/A
Revenue 1Y (TTM)6.04%
Revenue growth 3Y8.17%
Revenue growth 5Y6.8%
Sales Q2Q%-4.73%
Revenue Next Year-2.35%
Revenue Next 2Y1.33%
Revenue Next 3Y3.65%
Revenue Next 5YN/A
EBIT growth 1Y-652.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year611.66%
EBIT Next 3Y131.85%
EBIT Next 5YN/A
FCF growth 1Y-1114.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.64%
OCF growth 3Y-27.8%
OCF growth 5Y-12.64%